Atlas Trials

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Clinical trial NCT02572453 · TERMINATED

Trial details

NCT number
NCT02572453
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Mantle Cell LymphomaRefractory Transformed Non-Hodgkin Lymphoma
Start date
2016-04-04
Primary completion
2021-03-18
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.